We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Moderna COVID-19 Vaccine Provides Immunity for Three Months, Shows New NIAID Study

By HospiMedica International staff writers
Posted on 07 Dec 2020
Print article
Image: Moderna COVID-19 Vaccine Provides Immunity for Three Months, Shows New NIAID Study (Photo courtesy of Moderna, Inc.)
Image: Moderna COVID-19 Vaccine Provides Immunity for Three Months, Shows New NIAID Study (Photo courtesy of Moderna, Inc.)
Participants in the Phase 1 study of mRNA-1273, Moderna, Inc.’s (Cambridge, MA, USA) COVID-19 vaccine candidate, retained high levels of neutralizing antibodies through 119 days following first vaccination (90 days following second vaccination).

The interim durability data from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), follows the company’s November 30 announcement that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirmed the high efficacy observed at the first interim analysis. The data analysis indicated a vaccine efficacy of 94.1%. Author Alicia T. Widge M.D. of Vaccine Research Center, NIAID, NIH and others summarized that “mRNA-1273 produced high levels of binding and neutralizing antibodies that declined slightly over time, as expected, but they remained elevated in all participants three months after the booster vaccination.” These results were consistent across all age cohorts (18-55, 56-70 and 71+). The authors continued, “Although correlates of protection against SARS-CoV-2 infection in humans are not yet established, these results show that despite a slight expected decline in titers of binding and neutralizing antibodies, mRNA-1273 has the potential to provide durable humoral immunity.” They also reported that, “No serious adverse events were noted in the trial, no prespecified trial-halting rules were met, and no new adverse events that were considered by the investigators to be related to the vaccine occurred after day 57.”

“These interim Phase 1 data suggests that mRNA-1273, our COVID-19 vaccine candidate can generate durable neutralizing antibodies across all age groups including in older and elderly adults. Live virus and pseudovirus assay geometric mean titers (GMTs) remain high in the first months following vaccination,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer of Moderna. “These data give us further optimism to expect that the high level of efficacy recently demonstrated by mRNA-1273 to prevent COVID-19 disease will be durable.”

Moderna has also re-affirmed its expectation of having approximately 20 million doses available in the US by the end of 2020. Additionally, the company expects to have between 100 million and 125 million doses available globally in the first quarter of 2021, with 85-100 million of those available in the US and 15-25 million of those available outside of the US. These expected first quarter doses are inclusive within the 500 million to up to one billion doses that the company expects to manufacture globally in 2021.

Related Links:
Moderna, Inc.

Gold Supplier
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
New
Digital Video Colposcope
CS6/CS6 Pro
New
Mechanical Ventilator
NKV-550 Series
New
Portable Medical Air Compressor
EasyComp

Print article

Channels

AI

view channel
Image: MyoVista Wavelet technology utilizes AI for early detection of heart disease (Photo courtesy of Heart Test Laboratories)

Novel ECG Technology Utilizes AI for Early Detection of Heart Disease

Cardiovascular disease is responsible for 17.9 million deaths every year, or about 32% of all deaths worldwide. Every week, millions of electrocardiographs (ECGs) are performed across the world, making... Read more

Critical Care

view channel
Image: Studies have shown the Autus Valve maintains control of blood flow as it expands (Photo courtesy of Boston Children’s Hospital)

Heart Valve That Grows Along With Child Could Reduce Invasive Surgeries

In children with congenital pulmonary valve disease, the flow of blood between the heart and lungs is impeded. In cases where the pulmonary valves have narrowed or are leaking and cannot be treated effectively... Read more

Surgical Techniques

view channel
Image: The LithoVue Elite System (Photo courtesy of Boston Scientific)

First Ever Ureteroscope System Monitors Intrarenal Pressure in Real-Time During Ureteroscopy Procedures

About one in 10 people can develop a kidney stone at some point in their lives. Ureteroscopy is commonly performed by urologists to diagnose and treat various problems in the urinary tract, particularly... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.